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In Germany, routine childhood varicella vaccination 
was implemented in 2004 with two doses recom-
mended since 2009. We used an immunisation infor-
mation system based on countrywide health insurance 
claims data to analyse vaccine effectiveness (VE) and 
factors influencing VE. We applied proportional hazard 
models to estimate VE under various conditions and 
compared the risk of acquiring varicella among unvac-
cinated children in regions with high vs low vaccination 
coverage (VC). Among 1.4 million children we identi-
fied 29,404 varicella cases over a maximum follow-up 
of 8 years post-vaccination. One-dose VE was 81.9% 
(95% confidence interval (CI): 81.4–82.5), two-dose VE 
94.4% (95% CI: 94.2–94.6). With dose one given 1–27 
days after measles-containing vaccine (MCV), one-
dose VE was 32.2% (95% CI: 10.4–48.6), two-dose VE 
92.8% (95% CI: 84.8–96.6). VE was not associated 
with age at vaccination (11–14 vs ≥ 15 months), time 
since vaccination, or vaccine type. Unvaccinated chil-
dren had a twofold higher risk of acquiring varicella in 
low VC regions. Our system generated valuable data, 
showing that two-dose varicella vaccination provides 
good protection for at least 8 years. Unvaccinated chil-
dren benefit from herd effects. When the first varicella 
vaccine dose is given shortly after MCV, a second dose 
is essential.
Introduction
Immunisation Information Systems (IIS) are defined 
by the Centers for Disease Control and Prevention as 
confidential, population-based, computerised data-
bases that record all immunisation doses adminis-
tered by participating providers to persons residing 
within a given geopolitical area [1]. At the point of 
clinical care, IIS may support vaccination providers in 
decision-making towards appropriate individual vac-
cinations. At the population level, IIS provide aggre-
gate data on vaccinations for use in surveillance and 
programme operations, and in guiding public health 
action with the goals of improving vaccination rates 
and reducing vaccine-preventable disease. In 2004, 
Germany started to implement a nationwide IIS for the 
monitoring of vaccination coverage (VC) and selected 
vaccine-preventable diseases based on health insur-
ance claims data. The German IIS covers the statutory 
health-insured population (ca 85% of the total popula-
tion in Germany) and has proved to be a reliable source 
of VC data [2-5]. Moreover, the data were used to esti-
mate the incidence of selected vaccine-preventable 
diseases such as measles, mumps and herpes zoster 
in Germany [6-8]. Varicella is primarily clinically diag-
nosed [9], thus the German IIS seems suitable for the 
identification of varicella cases in the population.
Germany is one of the few countries worldwide that 
has introduced routine childhood varicella vaccination 
[10]. Since 2004, single-dose varicella vaccination has 
been recommended for all children aged 11–14 months. 
Two single-compound varicella vaccines (VAR; Varivax, 
Sanofi Pasteur MSD; Varilrix, GlaxoSmithKline) were 
initially available. In 2006, a combined measles-
mumps-rubella-(MMR)-varicella vaccine (MMRV; 
Priorix-Tetra, GlaxoSmithKline) was licensed with a 
two-dose schedule. A universal two-dose schedule 
has been recommended since 2009 targeting children 
with the second dose at age 15–23 months. Since 2011, 
the first immunisation has been given preferably as 
two separate injections of VAR and MMR due to higher 
rates of febrile seizures following immunisation with 
MMRV [11]. Catch-up vaccinations are recommended 
until 17 years of age.
The impact of routine varicella vaccination was ini-
tially monitored in a countrywide physician-based 
sentinel system. Sentinel data indicated a continuous 
overall 84% decrease of varicella cases per sentinel 
site between 2005 and 2012, most dominantly among 
1–4 year-olds [12]. Based on data from the IIS, VC in 
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24-month-old children increased nationwide in subse-
quent birth cohorts 2004–2009 from 43% to 87% (at 
least one dose) and from 1% to 64% (two doses) [3], 
whereas in the federal state of Saxony, varicella VC 
increased from 33% to 76% (at least one dose) and 
from < 1% to 24% (two doses). Within each birth cohort, 
the lowest VC was identified in the federal state of 
Saxony.
Several post-marketing studies on varicella vac-
cine effectiveness (VE) have been published [13-22]. 
However, of these, only few studies assessed the 
effectiveness of two doses [13-16]. In addition, little is 
known about the duration of vaccine-induced protec-
tion and the optimal age for vaccination [17-19]. Finally, 
there is little evidence on the minimum time interval 
between the first and second varicella vaccine dose as 
well as between varicella and measles-virus containing 
vaccines (MCV) [18,20].
We used data from the German IIS with the objectives 
to estimate dose-specific VE against all varicella, var-
icella-associated complications and varicella without 
complications, and to investigate factors that might 
influence VE, such as age at vaccination, time interval 
between varicella and MCV doses, type of vaccine, and 
time since vaccination (TSV). Furthermore, we aimed to 
quantify the degree of herd protection that is conferred 
in regions with high vs low VC.
Methods
Dataflow and database
Data were generated and collected within the German 
IIS, also called the ’Associations of Statutory Health 
Insurance Physicians (ASHIPs) vaccination monitoring 
project’. The system has been described in detail pre-
viously [3]. In brief, ASHIPs regularly receive insurance 
refund claims from all ASHIP-associated physicians 
for outpatient medical services provided to those cov-
ered by statutory health insurance. These claims data 
include all recommended vaccinations and diagnosed 
diseases. The latter have to be documented in order 
to justify medical services. Approximately 85% of the 
population in Germany is covered by statutory health 
insurance. The remainder are mainly privately insured. 
The administrative regions of most ASHIPs are organ-
ised by federal state. Data relevant for the project are 
extracted from the ASHIPs’ databases and anonymised. 
Data are quarterly transferred to the Robert Koch 
Institute (RKI, German national public health institute), 
and imported into a central database. Since 2006, the 
database contains patient information, data on vacci-
nations and diagnoses of selected vaccine-preventable 
diseases, and since 2008, dates of individuals’ physi-
cian consultations (Table 1).
Data protection
The Federal Commissioner for Data Protection and 
Freedom of Information in Germany has approved the 
ASHIP vaccination monitoring project.
Sampling and data preparation
The unique patient identifier in the anonymised data 
is generated differently between ASHIPs. Therefore, 
medical services received by a single patient can only 
be assigned to a unique patient identifier in the data 
anonymised by a single ASHIP but not by different 
ASHIPs. As a consequence, we would identify an indi-
vidual receiving the first varicella vaccine dose in one 
ASHIP region and the second dose in another region 
(e.g. due to moving into another federal state) as two 
individuals in the central database, both with incom-
plete vaccination series. For this reason, we selected 
individuals according to inclusion criteria as described 
previously [2,3]: Any individual (i) born between 
January 2006 and October 2013, (ii) receiving any vac-
cination (i.e. not necessarily varicella) soon after birth 
at 0–4 months of age, (iii) with contact with a physi-
cian within the second half of 2015, (iv) residing at the 
time points of (ii) and (iii) in the region of the ASHIP 
that transferred the data, and (v) born in an ASHIP 
region where diagnosis information was available and 
specific vaccination claim codes for varicella vaccines 
had been introduced since birth. Within this sampling 
period, i.e. from birth to the second half of 2015, the 
actual analysis time in the follow-up period went from 
the quarter in which the child turned 11 months until 
June 2015 at maximum. We assumed included children 
presented at physicians exclusively within their associ-
ated ASHIP region during the follow-up period because 
both in the beginning and in the end of the period, phy-
sician contacts were documented within their resident 
ASHIP region.
Data from 12 of 17 ASHIP regions were analysed, start-
ing from either birth cohort 2006 (ASHIPs Brandenburg, 
Hamburg, Mecklenburg-West Pomerania, Lower 
Saxony, Saarland, Saxony-Anhalt, Schleswig-Holstein, 
Thuringia) or later birth cohorts due to late introduction 
of MMRV-specific claim codes, i.e. birth cohort 2007 
(ASHIP Saxony) or 2008 (ASHIPs Baden-Württemberg, 
North Rhine, Berlin). Data from the remaining ASHIPs 
were either missing for several years, did not con-
tain the variable ‘diagnosis type’, or were incomplete 
regarding physician contacts.
We applied a four-step algorithm to only select con-
firmed and incident (diagnosis type: current state) vari-
cella diagnoses and to limit these to the earliest and to 
the most severe varicella diagnosis for each selected 
patient as described previously [6,7]. Briefly, step 1 
excluded incompatible or implausible coding combina-
tions for varicella diagnosis reliability; step 2 excluded 
observations with diagnosis reliability other than con-
firmed (i.e. suspected, excluded, recovered); step 3 
excluded observations with diagnosis type other than 
incident (i.e. previous state, unknown, not provided); 
step 4 limited the data selection to the earliest ICD-10 
code per patient while, in addition, keeping the infor-
mation about the most severe ICD-10 code (within up 
to one quarter following the initial diagnosis) using 
the following ranking (in descending order of severity): 
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varicella with encephalitis, meningitis, pneumonia, 
other complications, no complications, no further 
details, with the latter equalling ‘no complications’.
The date of diagnosis was quarter-specific. Therefore, 
the unit of analysis time used in our models was one 
quarter of a year. Individual analysis time in the mod-
els started with the quarter in which the child turned 11 
months of age (i.e. the ’entry’ in the time-series analy-
sis), and lasted until the last quarter of the follow-up 
period (i.e. the ‘exit’). We reduced the vaccination date 
from day-specific to quarter-specific for calculations 
of analysis time. Children with varicella vaccinations 
and/or a varicella diagnosis before the entry quarter 
were excluded from VE analysis. Due to the granular-
ity of the date of diagnosis, we could reliably identify 
breakthrough infections, defined as varicella infection 
being diagnosed ≥ 42 days post vaccination, only when 
the vaccine was received at least three quarters pre-
ceding the diagnosis. We therefore excluded the first 
two quarters of analysis time of each vaccination sta-
tus of a patient in the time-series models. Hence, this 
excluded patients with half a year or less of analysis 
time. We also excluded children where sex was not 
recorded and those with presumably erroneous docu-
mented VAR plus MMRV or MMRV plus MMR vaccina-
tions on the same day.
Data analysis
Individual histories of first and second varicella vac-
cination and varicella diagnosis were set up for time-
series analysis in Stata 13 (StataCorp, US). We used 
Cox-like piecewise proportional hazard models allow-
ing for the analysis of potentially varying hazard ratios 
over TSV. We stratified the observations at an individ-
ual level into the period of > 0.5–1.0 years TSV and seven 
annual periods from > 1.0–2.0 to > 7.0–8.0 years TSV to 
analyse VE by TSV. For all other analyses of VE, we did 
not stratify the observation periods but performed the 
analysis over the whole TSV beginning at > 0.5 years 
TSV. The individual analysis time either ended due to 
censoring or failure, respectively, or stopped with each 
change of vaccination status while restarting at zero 
with assigning the patient’s new vaccination status.
We verified the proportional hazard assumption – a 
prerequisite for modelling Cox regression for time-
series data – for each covariate and globally at the stra-
tum level using formal significance tests and graphical 
evaluation of unscaled and scaled Schoenfeld residu-
als. Additionally, we performed graphical assessment 
of proportional hazards using log-log survival curves.
In the Cox regression model we used vaccination sta-
tus and TSV as the categorical predictor variables. We 
stratified by sex, year of birth, and ASHIP to ensure 
comparing children of similar age and region. Strata 
were weighted using probability weights generated 
from sex-, birth cohort-, and ASHIP region-specific 
live-births and sample size (German Federal Statistical 
Office; State Office for Information and Technology 
North Rhine-Westphalia).
We calculated VE as ‘(1-hazard ratio) x 100’, and mod-
elled incremental VE as the additional effectiveness 
provided by the second dose compared with a single 
dose ([VE2-VE1] / [100-VE1] x 100). We calculated VE in 
the whole sample but also by exclusion of children with 
incompliant spacing of vaccinations, i.e. varicella vac-
cinations given 1–27 days after MCV or subsequent var-
icella vaccine doses administered within 1–27 days. In 
addition, we built models which were either extended 
by the inclusion of variables for (i) type of vaccine (VAR, 
MMRV), (ii) age at first varicella vaccination (11–14 
months; > 15 months of age), (iii) time to varicella vac-
cination following MCV (same day as MCV or > 27 days 
after MCV; incompliant spacing) excluding patients 
with incompliant spacing between varicella vaccina-
tions, or (iv) time between first and second varicella 
vaccination (incompliant spacing; 28–365 days; > 1–3 
years; > 3 years) excluding patients with incompliant 
spacing to MCV. We defined one group of outcome (no 
complications) as failure and censored the patient in 
presence of the remaining outcome group (complica-
tions) and vice versa to estimate VE for the prevention 
of varicella-associated complications vs no complica-
tions. Using the Wald test, we tested for significant 
differences of coefficients and their interactions and 
applied a Bonferroni correction to the p  values when 
multiple testing was performed.
The cumulative baseline hazards in the time-series 
analyses are the stratum-specific cumulative hazards 
in unvaccinated children. We used these to estimate 
morbidity among unvaccinated children stratified by 
sex, birth cohort and ASHIP. We used linear regres-
sion to summarise these cumulative hazards for both 
Saxony, an area with low VC, and the remaining ASHIP 
regions. The ratio of these mean cumulative hazards 
was used to compare the different degree of protection 
in regions with different VC. The risk R(t) of acquiring 
varicella up to time t can be derived from the cumula-
tive hazard H(t) by applying the formula 
In addition, we calculated attack rates from the obser-
vational data using probability weights (Pearson test 
statistics of the survey procedures in Stata) for Saxony 
and outside Saxony and compared them with each 
other in a rate ratio. We set the significance level to 
0.05.
We calculated longitudinal VC both in Saxony and the 
remaining ASHIP regions as described previously by 
counting age-specific doses at an individual level by 
ASHIP/year  of  birth/sex and subsequent aggregation 
to VC by age within and outside Saxony [2,3].
4 www.eurosurveillance.org
Results
Between January 2006 and October 2013, a total of 
5,294,301 live births were registered in Germany, of 
which 2,790,220 children (53%) were born in the inves-
tigated ASHIP regions and years of birth. Among those, 
1,449,411 children (52%) were available for VE analysis 
(range over regions and years of birth: 35–69%). Their 
characteristics are given in Table 2.
Overall vaccine effectiveness
Over the total observation period and after exclusion 
of children with incompliant spacing between vaccine 
doses, VE for one dose (VE1) was 81.9% (95% confi-
dence interval (CI): 81.4–82.5) and significantly lower 
(p < 0.0001) than VE2 with 94.4% (95% CI: 94.2–94.6) 
(Table 3). The incremental VE of adding a second 
dose to the first dose was 68.9% (95% CI: 67.5–70.1). 
Stratified by sex, the VE1 difference was less than 2 
percentage points and slightly higher in females as 
compared with males (82.8% vs 81.1%, p = 0.0015); for 
VE2, the difference was even smaller (94.6% vs 94.2%, 
p = 0.0072). The inclusion of children with incompliant 
spacing had nearly no influence on VE (Table 3).
Vaccine effectiveness by time since vaccination 
and age
While VE1 increased over time from 79.4% (95% CI: 
78.2–80.5) at > 0.5–1.0 year TSV to 88.0% (95% CI: 
76.6–93.8) at > 7.0–8.0 years TSV, VE2 remained stable 
at > 92.0% (Table 4).
Within the first year since vaccination, both VE1 and 
VE2 were slightly but significantly lower than in the 
following 3–5 time intervals. When stratifying by vac-
cine type, VE1 from VAR stayed in the same magnitude 
over time (80.6% (95% CI: 78.8–82.3) at > 0.5–1.0 year 
TSV; 78.4% (95% CI: 47.7–91.1) at > 7.0–8.0 years TSV) 
whereas VE1 from MMRV increased from 78.0% (95% 
CI: 76.4–79.5) to 92.0% (95% CI: 78.3–97.1). VE1 did 
not differ by age at first vaccination (82.1%; 95% CI: 
81.4–82.8 in age group 11–14 months and 81.5%; 95% 
CI: 80.6–82.3 at ≥ 15 months; Table 3).
Effect of time between subsequent live 
attenuated vaccine doses
A single varicella vaccination given 1–27 days after MCV 
conferred significantly lower protection (VE1 = 32.2%, 
95% CI: 10.4–48.6) than a single dose given simulta-
neously or > 27 days after MCV (80.9%, 95% CI: 80.2–
81.5) (Table 3). VE2 was not reduced when only one of 
the two doses was administered 1–27 days after MCV.
Two varicella vaccinations administered in an interval 
of 28–365 days gave statistically similar VE2 as vac-
cinations given 1–27 days, > 1–3 years or > 3 years apart. 
The VE2 estimate for varicella vaccinations 1–27 days 
apart was based on only 305 patients, was ca 8 per-
centage points lower than with any other time interval 
and had a wide 95% CI.
Vaccine effectiveness by vaccine type
We found similar VE1 for VAR and MMRV (82.0% (95% 
CI: 81.0–82.9) vs 81.7% (95% CI: 81.0–82.4), respec-
tively) (Table 3). VE2 for all combinations of VAR and 
MMRV as first or second dose were also similar and 
Figure 1
Cumulative coverage by age in the federal state of Saxony 
(n = 179,162) and other regions of Germany (n = 1,760,220) 
for one and two varicella vaccinations for all ASHIPs and 
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ASHIP: Association of Statutory Health Insurance Physicians.
Figure 2
Cumulative hazard in ASHIP/year of birth/sex strata by 
analysis time in time-series analysis and linear fit among 
unvaccinated children in the federal state of Saxony 
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ASHIP: Association of Statutory Health Insurance Physicians.
Analysis time 0–0.5 years was omitted from hazard analysis. At 
time = 0, children are ca 11 months.
Linear fit (p < 0.001, R-squared = 0.94).
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ranged between 94.3% (95% CI: 93.9–94.8) and 95.0% 
(95% CI: 94.3–95.5).
Protection against complicated vs non-
complicated varicella
VE against varicella-associated complications 
(VE1 = 98.2%, 95% CI: 98.0–98.5; VE2 = 99.5%, 95% 
CI: 99.4–99.5) was significantly higher than against 
non-complicated varicella (VE1 = 65.3%, 95% CI: 64.2–
66.4; VE2 = 89.3%, 95% CI: 89.0–89.7) with two doses 
being significantly more effective than a single dose.
Risk of acquiring varicella among unvaccinated 
children
VC in Saxony was lower than in other ASHIP regions 
over the whole age-range covered in the sample; e.g. at 
24 months of age VC1 was 73.2% and VC2 was 25.3% in 
Saxony vs 90.1% and 68.3% outside Saxony (Figure 1).
The attack rate of varicella in unvaccinated children 
was 12.6% (95% CI: 12.3–12.9) in Saxony vs 5.8% (95% 
CI: 5.7–5.9) in other regions translating into a rate 
ratio of 2.2 (95% CI: 2.1–2.2; p < 0.0001). The cumula-
tive hazard and the risk of acquiring varicella among 
unvaccinated children were around two times higher 
in Saxony; e.g. after 4 years of analysis time we cal-
culated a ratio of the cumulative hazards of 2.4 and a 
risk ratio of 2.2 corresponding to a cumulative hazard 
of 27.4% (95% CI: 27.4–27.5) in Saxony vs 11.3% (95% 
CI: 11.3–11.3) outside of Saxony, and after 7.5 years of 
analysis time the ratio of the cumulative hazards was 
2.4 and the risk ratio 2.0, corresponding to a cumula-
tive hazard of 58.3% (95% CI: 58.3–58.3) in Saxony vs 
24.6% (95% CI: 24.6–24.6) in other regions (Figure 2).
Discussion
Starting from diagnoses and administered vaccinations 
as documented in health insurance claims and linked 
at the individual level, our analysis shows that the 
German IIS is a potent system for the continuous moni-
toring not only of VC but also of the effectiveness of 
vaccination and the impact of vaccination at the popu-
lation level after widespread use. Our data confirm the 
additional effect of a second varicella vaccine dose 
and demonstrate indirect protection of unvaccinated 
individuals in areas with high VC.
Evidence on the loss of vaccine-induced protection 
after one dose has been inconclusive in previous 
studies [17-19]. Our data demonstrate the absence of 
waning of vaccine-induced protection by one and two 
doses over at least eight years. However, after the sec-
ond dose, protection is much higher in each observed 
time interval after vaccination, with an overall incre-
mental effectiveness of 68.9%. The result for VE1 is in 
line with data from a case–control study and a time-
series approach in Germany where 86.4% and 83.2% 
were estimated [21,22]. Our findings are also compa-
rable to the results of a recent German study based 
on the screening method and to international data 
from case–control studies where VE1 and VE2 were at 
80–87% and 97–98%, respectively [13,14,15,23-26]. In 
addition, a 2016 meta-analysis of literature published 
between 1995 and 2014 on VE among healthy children 
reported similar results with a pooled VE1 of 81% (95% 
CI: 78–84) and a pooled VE2 of 92% (95% CI: 88–95) 
[27].
We found similar VE1 irrespective of young or older age 
at vaccination. Previously, evidence for vaccination at 
young age as a potential risk factor for vaccine failure 
has been reported inconclusively [28,29]. Our findings 
support the current national immunisation scheme rec-
ommending the first varicella dose at young age (from 
as early as 11 months) as recommended in the major-
ity of countries that have adopted varicella vaccination 
[30].
VE1 was strongly reduced when the first varicella vac-
cination was administered with incompliant spacing 
to MCV. In contrast, VE2 estimates were not affected 
when one of the doses (first or second) were given 
with incompliant spacing to MCV. Due to small sample 
size, VE2 under the condition of both doses given with 
incompliant spacing could not be analysed. A higher 
risk for varicella due to a short spacing between the 
administration of MCV and a single varicella vaccine 
dose has been described previously [29]. Generally, 
a minimal time interval for the administration of live 
attenuated vaccines is recommended to avoid poten-
tial suppressive effects on the immune response. To 
our knowledge this has only been studied for vaccina-
tions given up to 4 weeks after MMR vaccinations but 
not for successive varicella vaccinations [29,31,32]. 
In contrast to our result that two varicella vaccine 
doses may compensate the reduced VE of one dose 
given too early after MCV, the VE2 point estimate of 
the 1–27-day time interval between varicella vaccine 
doses was lower than for longer intervals. However, 
the sample size was small and the decrease was sta-
tistically non-significant. Still, this might indicate that 
a short spacing of subsequent varicella vaccinations 
negatively affects VE. This is of particular importance 
for accelerated schedules in situations like outbreaks, 
urgent catch-ups and for rapid immunisations before 
travelling. Overall, simultaneous administration of 
MCV and varicella vaccine or a time interval > 27 days 
between these vaccinations or between subsequent 
varicella vaccinations seemed to confer optimal protec-
tion against varicella. We found no significant differ-
ence in VE2 in all investigated time intervals > 27 days 
up to > 3years between varicella doses, indicating that 
different national or regional recommendations regard-
ing this interval will lead to similar VE2. This observa-
tion and our result that vaccine-induced protection is 
not waning, support the current recommendation in 
Germany for a second dose given early in childhood.
We found no statistical difference in VE from single-
compound vs combined vaccines, neither for one dose 
nor in any two-dose combination. Also at the level of 
point estimates, VE was virtually similar. Although 
Spackova et al. identified differences in relative risk 
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point estimates for breakthrough infections by type 
of vaccine, their findings concerning the use of two 
single-compound vaccines and MMRV were non-signif-
icant [16]. Our finding shows that in particular the cur-
rently recommended combination of VAR followed by 
MMRV in Germany confers the same protection as any 
other combination.
Our results show that a single dose better protects 
against a more serious course of infection than against 
mild varicella. A second dose only adds a small addi-
tional benefit in this regard. Our results point towards 
the same direction as the results of previous observa-
tions, although the observed endpoints were different 
(recorded codes of diagnosis in our study vs observed 
symptoms or number of lesions in other studies) [27].
We found an around twofold higher attack rate and risk 
of acquiring varicella in unvaccinated children in Saxony 
vs other ASHIP regions. Saxony has a much lower VC 
for both first and second dose varicella vaccination 
than any other ASHIP region in Germany. Similar find-
ings are annually published based on cross-sectional 
analyses from nationwide school entrance examina-
tions [33]. Having its own state level advisory commit-
tee on immunisation, Saxony recommended until the 
end of 2014 the second varicella dose from five years 
of age [34]. The lower risk of acquiring varicella in the 
unprotected population in regions of Germany that 
have higher varicella VC than Saxony is a strong indi-
cation for the presence of herd effects. Varicella herd 
protection was described previously based on health 
insurance claims data showing a decline in varicella 
outpatient visits and hospitalisations among infants 
Table 1
Database content relevant to varicella disease and 
vaccination in the German Associations of Statutory 
Health Insurance Physicians vaccination monitoring 
project
Patient information 
Anonymised unique identifier 












B01. Varicella [chickenpox] 
B01.0 Varicella meningitis 
B01.1 Varicella encephalitis 
B01.2 Varicella pneumonia 
B01.8 Varicella with other 
complications 













Quarter and year of 
diagnosis
Physician contact information 
Physician’s ASHIP 
Date of patients’ first contact per quarter and medical 
specialisation 
ICD-10: International Classification of Diseases, 10th revision [38]; 
ASHIP: Associations of Statutory Health Insurance Physicians.
Table 2
Data characteristics of individuals analysed in the time-
series models for varicella vaccine effectiveness estimates, 
Germany, 2006–2015
Characteristics Measure 
Number of subjects (%) 1,449,411 (100)
Number of females (%) 704,036 (48.6)
Number of varicella cases (%) 29,404 (2.0)
Mean years of age at diagnosis 3.6
Number of cases with complications (% 
among cases) 1,213 (4.13)
Encephalitis (% among cases) 33 (0.11)
Meningitis (% among cases) 129 (0.44)
Pneumonia (% among cases) 9 (0.03)
Other (% among cases) 1,042 (3.54)
Mean years of individual analysis time (total 
personyears) 3.0 (4,332,641)
Number of individuals receiving varicella 
vaccination (%) 
No vaccination 92,712 (6.4)
1st dose 1,298,697 (89.6)
2nd dose 1,090,969 (75.3)
Number of administered vaccine type (%) 
1st VAR 490,002 (33.8)
1st MMRV 808,695 (55.8)
2nd VAR 87,504 (6.0)
2nd MMRV 1,003,465 (69.2)
Mean months of age at vaccination 
1st dose 15
2nd dose 22
Number of individuals receiving 1st vaccination by age (% among 
1st doses) 
11–14 months 1,030,331 (79.3)
≥ 15 months 268,366 (20.7)
Number of subjects with varicella vaccination after MCV (%) 
At least one dose 1–27 days 5,434 (0.4)
All doses same day or > 27 days 1,293,263 (89.2)
Number of 2nd vaccinations by distance to 1st dose (% among 
2nd doses) 
1–27 days 2,862 (0.3)
28–365 days 919,711 (84.3)
> 1 year–3 years 148,198 (13.6)
> 3 years 20,198 (1.9)
MCV: measles containing vaccine; MMRV: measles-mumps-rubella-
varicella vaccine; VAR: single-compound varicella vaccine.
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and adults not targeted for vaccination in the United 
States [35].
The basis for our analyses are health insurance claims 
data primarily generated for the reimbursement of 
medical services provided by physicians. They have 
not been created for the purpose of answering epi-
demiological questions in secondary data analyses. 
However, reimbursement for vaccinations is directly 
linked to correct code usage. Hence, validity of vac-
cination data can be expected to be very high as we 
have previously shown [3]. Still, several MMRV claim 
code changes occurred soon after its availability. 
Wrong usage will have led to misclassification of a sec-
ond MMRV dose as the first dose in our IIS, which was 
more likely in the early years of the programme. This 
explains the increase of VE1 over higher intervals of 
TSV from MMRV but not VAR. Therefore, VE1 estimated 
from VAR may be a more accurate representation of VE 
over TSV. VE1 measured from both VAR and MMRV in 
the overall analysis, however, is nearly similar to VE1 
measured from VAR alone suggesting that the potential 
misclassification is of minor consequence.
Our IIS covers all individuals in Germany with statu-
tory health insurance. Between 2006 and 2015, an 
Table 3
Varicella vaccine effectiveness from > 0.5 to 8.0 years since vaccination based on estimates from time-series analysis, 
Germany, 2006–2015 (n = 1,449,411)
Overall (excluding patients receiving varicella vaccinations 1–27 days 
after MCV or 1st and 2nd dose varicella 1–27 days apart)
VE1 (95% CI) VE2 (95% CI)
81.9 (81.4–82.5) 94.4 (94.2–94.6)
Overall 81.8 (81.2–82.4) 94.4 (94.2–94.6)
Age at 1st vaccinationa
11–14 months 82.1 (81.4–82.8)   
NA≥ 15 months 81.5 (80.6–82.3)
Varicella vaccination after MCV (excluding patients receiving 1st and 2nd dose varicella 1–27 days apart)b
2nd dose 1–27 days 2nd dose same day or > 27 days
1st dose 1–27 days 32.2 (10.4–48.6)
No meaningful 
estimate 
(n = 26; 1 varicella 
case)
92.8 (84.8–96.6)
1st dose same day or > 27 days 80.9 (80.2–81.5) 95.3 (66.6–99.3) 94.1 (93.9–94.3)









28–365 days 94.4 (94.2–94.6)
> 1–3 years 94.8 (94.4–95.2)
> 3 years 95.0 (93.6–96.1)
Vaccine typed
2nd dose VAR 2nd dose MMRV
1st dose VAR 82.0 (81.0–82.9) 95.0 (94.3–95.5) 94.3 (93.9–94.8)
1st dose MMRV 81.7 (81.0–82.4) 94.4 (93.4–95.2) 94.4 (94.2–94.6)
Prevention of uncomplicated/complicated casese,f
No complication 65.3 (64.2–66.4) 89.3 (89.0–89.7)
NA
All complications 98.2 (98.0–98.5) 99.5 (99.4–99.5)
CI: confidence interval; MCV: measles containing vaccine; MMRV: measles-mumps-rubella-varicella combination vaccine; NA: not applicable; 
VAR: single-compound varicella vaccine; VE: vaccine effectiveness; VE1: vaccine effectiveness for one dose; VE2: vaccine effectiveness for 
two doses.
a VE1 difference not significant.
b Within VE1, VE is significantly different (p < 0.0001); within VE2 and where applicable, no combination with VE from both doses administered 
0 / > 27 days apart significantly different.
c No combination with VE at 28–365 days significantly different.
d Within VE1 and VE2, no combination significantly different.
e In contrast to the outcome ‘varicella’ in the majority of models, here we defined ‘varicella without complications’ as failure and censored the 
patient in presence of ‘varicella with associated complications’ and vice versa to estimate VE.
f Within VE1 and VE2 and between VE1 and VE2 difference significant (all p < 0.0001).
All given VE estimates are significant.
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average of 83% among 0–14 year-olds (range between 
ASHIP regions: 81–89%) were statutory health insured 
(statistics of statutory health insurees by the German 
Ministry of Health; population statistics by the Federal 
Statistics Office). Both statutory and private health 
insurances fully reimburse recommended vaccina-
tions. The authors of a large population-based cross-
sectional study found no difference in the proportions 
of undervaccinated children when comparing children 
from parents with statutory and private health insur-
ance [36]. Thus, we assume comparable VC and VE in 
children not covered by the IIS.
Diagnoses from health insurance claims data have 
been exploited for measles incidence estimation and 
showed trends and variation similar to outpatient noti-
fication data estimates supporting their usefulness for 
epidemiological analyses [7]. However, there are no 
standardised guidelines for coding and updating diag-
noses as ‘confirmed’ or ‘suspected’ disease. The physi-
cian does not require laboratory confirmation for this 
classification and may solely rely on clinical symptoms. 
Since we used only confirmed cases, our sampling 
approach for cases might have been rather conserva-
tive. Nonetheless, physicians may feel more confident 
in classifying a diagnosis as confirmed in unvaccinated 
cases. Because patients with mild disease are less 
likely to present at their physician while the probability 
for a mild course of the disease is higher for vaccinated 
cases, a bias might have been introduced in our study 
population which would result in an overestimation 
of overall VE but not VE for the prevention of severe 
varicella. We identified 4.13% of complications among 
all cases. This is in line with previous reports of 2–6% 
of cases with complications attending a general prac-
tice [37]. However, since health insurance claims data 
only cover outpatient data and complicated cases are 
more likely to be hospitalised and less likely to (at least 
initially) present as outpatient case, these cases are 
possibly underrepresented in our sample and therefore 
not included in the analysis. In 2004, a total of 2,316 
hospitalised varicella cases were recorded in the sta-
tistics of hospital diagnoses followed by a decreasing 
trend to around 1,000 cases from 2008 until 2014 and 
an increase to 1,504 cases in 2015 (Federal Statistics 
Office). The decrease was especially prominent in chil-
dren below 5 years of age, ranging from 1,139 cases in 
2004 to 159 and 207 cases in 2014 and 2015, respec-
tively. Since severity is associated with not being 
vaccinated, hospitalised cases among unvaccinated 
children may be disproportionately underrepresented 
in our sample. This bias may have led to a slight under-
estimation of our calculated VE.
Our IIS was implemented in 2004 and – after suc-
cessful validations and extensive piloting – serves 
as a unique source to monitor and evaluate vaccina-
tion recommendations and strategies in Germany. The 
system provides VC data for the international report-
ing to the World Health Organization and informs 
the National Verification Committee for Measles and 
Rubella Elimination on the elimination progress in 
Germany, since it currently offers the only nationwide 
data source to estimate VC in various age groups. In 
Table 4
Varicella vaccine effectiveness by time since vaccination and vaccine-type estimated from time-series analysis using 





VE1 (95% CI) 
VAR
VE1 (95% CI) 
MMRV VE2 (95% CI) Effective sample size
na n0dose n1dose n2dose 






(92.7–93.5) 1,449,411 275,814 527,514 1,090,969






94.5) b 1,259,119 176,424 264,220 972,827






95.5) b 956,643 101,550 127,393 756,329






95.2) b 708,054 65,970 79,938 566,342






95.2) b 467,703 43,092 48,090 376,531






95.7) b 265,351 26,302 25,218 213,831






(91.7–94.6) 114,503 13,249 12,172 89,082






(88.3–95.0) 40,806 6,038 5,050 29,718
CI: confidence interval; MMRV: measles-mumps-rubella-varicella vaccine; VAR: single-compound varicella vaccine; VE1: vaccine effectiveness 
for one dose; VE2: vaccine effectiveness for two doses.
a Total sample may be smaller than the sum of vaccination status specific sample sizes as a single patient may have several vaccination 
statuses within one analysis period.
b Within VE1 or VE2, respectively, significantly different to VE > 0.5–1.0 years since vaccination.
9www.eurosurveillance.org
addition, since vaccination claims and disease codes 
can be linked at an individual level and the IIS cap-
tures a large proportion of the total population, it pro-
vides the opportunity to assess VE and vaccination 
programme impact at a population level. When the 
German Standing Committee on Vaccination initially 
endorsed the two-dose recommendation for varicella 
vaccination, it requested an evaluation by 2013. The IIS 
was one of four surveillance data sources that contrib-
uted to this evaluation [20]. There were some remaining 
questions that we were able to address in the present 
study, namely the duration of varicella vaccine-induced 
protection after two doses, the optimal age for the sec-
ond dose, and potential differences in VE between the 
available varicella vaccine types.
By demonstrating that we were able to answer impor-
tant questions related to the national varicella vac-
cination programme, we conclude that our IIS is an 
indispensable system not only for the assessment of 
VC in various age groups and geographical regions 
in Germany, but also for the monitoring and in-depth 
evaluation of national vaccination recommendations 
and strategies.
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